Ticker

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $6.40, for a total value of $49,587.20. Following the completion of the sale, the insider owned 387,769 shares in the company, valued

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52. Following the completion of the transaction, the insider owned 395,517 shares in the company,

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 25,040 shares of Clene stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20. Following the completion of the sale, the insider owned 362,729 shares of the company's stock,

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 O versubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through…

SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS),…